Novo launches type 2 diabetes pill in UK after NICE waives reviewNovo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost-effectiveness watchdog NICE Share XNovo launches type 2 diabetes pill in UK after NICE waives reviewhttps://pharmaphorum.com/news/novo-launches-type-2-diabetes-pill-in-uk/
Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetesIn our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he Share XNovo Nordisk: Prevention, digital tools and collaboration to define the future of diabeteshttps://pharmaphorum.com/views-analysis-sales-marketing/novo-nordisk-prevention-digital-tools-and-collaboration-to-define-the-future-of-diabetes/
Novo Nordisk beats Q2 profit forecasts by cutting costsDenmark’s Novo Nordisk has beaten profit forecasts in the second quarter after overcoming tough conditions in the diabetes Share XNovo Nordisk beats Q2 profit forecasts by cutting costshttps://pharmaphorum.com/news/novo-nordisk-beats-q2-profit-forecasts-by-cutting-costs/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
Novo Nordisk diversifies with $2.1bn deal to buy CorvidiaNovo Nordisk has taken another step towards expanding beyond its heartlands of diabetes and obesity with a deal Share XNovo Nordisk diversifies with $2.1bn deal to buy Corvidiahttps://pharmaphorum.com/news/novo-nordisk-diversifies-with-2-1bn-deal-to-buy-corvidia/
Coronavirus to disrupt EU pharma drug launches, analysts warnBig European launches of drugs for cancer, HIV, and sickle cell disease could be affected by coronavirus, according Share XCoronavirus to disrupt EU pharma drug launches, analysts warnhttps://pharmaphorum.com/news/coronavirus-to-disrupt-eu-pharma-drug-launches-analysts-warn/
Could GLP-1 drugs treat space headaches? NASA wants to know.Experts from NASA are keeping a close eye on UK research that tests whether drugs commonly used in Share XCould GLP-1 drugs treat space headaches? NASA wants to know.https://pharmaphorum.com/news/nasa-looks-on-as-uk-researchers-test-glp-1-drugs-against-space-headaches/
FDA approves MACE label claim for Lilly’s TrulicityEli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for Share XFDA approves MACE label claim for Lilly’s Trulicityhttps://pharmaphorum.com/news/fda-approves-mace-label-claim-for-lillys-trulicity/
Ozempic acceleration buoys Novo Nordisk, and threatens LillySolid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat Share XOzempic acceleration buoys Novo Nordisk, and threatens Lillyhttps://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/
